United States Biotechnology & Medical Research

Evelo Biosciences Inc (EVLO)

Track

Track

Ticker: EVLO Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Evelo Biosciences Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
McHale Duncan Chief Medical Officer Officer
Transaction date
Planned sale
Price
349.68
Quantity 2,721 +44.6%
Value US$3,193,289
Bodmer Mark CSO, President of R&D Officer
Transaction date
Planned sale
Price
251.07
Quantity 3,260 +48.2%
Value US$722,161
Thorell Marella Chief Financial Officer Officer
Transaction date
Planned sale
Price
30.68
Quantity 16,930 -33.7%
Value US$2,977,715
GILL SIMBA President & CEO Executive Director
Transaction date
Planned sale
Price
0.33
Quantity 172 -1.0%
Value US$57
Thorell Marella Chief Financial Officer Officer
Transaction date
Planned sale
Price
0.33
Quantity 3,999 -18.5%
Value US$1,320
Bodmer Mark CSO, President of R&D Officer
Transaction date
Planned sale
Price
0.33
Quantity 6,854 -23.5%
Value US$2,262
McHale Duncan Chief Medical Officer Officer
Transaction date
Planned sale
Price
0.33
Quantity 6,854 -33.5%
Value US$2,262
GILL SIMBA President & CEO Executive Director
Transaction date
Planned sale
Price
3.94
Quantity 1,996 -10.6%
Value US$7,864
Thorell Marella Chief Financial Officer Officer
Transaction date
Planned sale
Price
9.51
Quantity 2,004 -18.1%
Value US$19,058
GILL SIMBA President & CEO Executive Director
Transaction date
Planned sale
Price
9.51
Quantity 342 -8.3%
Value US$3,252
Bodmer Mark CSO, President of R&D Officer
Transaction date
Planned sale
Price
9.51
Quantity 3,128 -15.8%
Value US$29,747
McHale Duncan Chief Medical Officer Officer
Transaction date
Planned sale
Price
9.51
Quantity 3,434 -30.2%
Value US$32,657
Bodmer Mark CSO, President of R&D Officer
Transaction date
Planned sale
Price
0.14
Quantity 22,571 -7.9%
Value US$3,201
Thorell Marella Chief Financial Officer Officer
Transaction date
Planned sale
Price
0.13
Quantity 38,531 -29.6%
Value US$4,836
Bodmer Mark CSO, President of R&D Officer
Transaction date
Planned sale
Price
0.13
Quantity 68,014 -19.3%
Value US$8,536
GILL SIMBA President & CEO Executive Director
Transaction date
Planned sale
Price
0.13
Quantity 3,537 -5.7%
Value US$444
McHale Duncan Chief Medical Officer Officer
Transaction date
Planned sale
Price
0.13
Quantity 66,730 -40.6%
Value US$8,375
CARRIERE STEPHEN J Principal Accounting Officer Officer
Transaction date
Sale
Price
1.06
Quantity 151 -42.7%
Value US$160
Darzi Lord Ara Non-Executive Director
Transaction date
Purchase
Price
1.46
Quantity 342,465 +inf%
Value US$499,999
McHale Duncan Chief Medical Officer Officer
Transaction date
Purchase
Price
1.46
Quantity 34,246 +inf%
Value US$49,999
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
1.46
Quantity 17,123 +25.6%
Value US$25,000
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
7.02
Quantity 200 +1.1%
Value US$1,404
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
6.98
Quantity 500 +2.9%
Value US$3,490
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
6.91
Quantity 1,000 +6.2%
Value US$6,910
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
7.16
Quantity 800 +5.3%
Value US$5,728
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
6.49
Quantity 4,970 +48.6%
Value US$32,255
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
6.45
Quantity 30 +0.3%
Value US$194
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
6.40
Quantity 200 +2.0%
Value US$1,280
Liu Xiaoli Jacqueline Principal Accounting Officer Officer
Transaction date
Sale
Price
5.17
Quantity 3,000 -100.0%
Value US$15,510
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
4.58
Quantity 1,000 +11.1%
Value US$4,580
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
4.48
Quantity 1,000 +12.5%
Value US$4,480
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
4.47
Quantity 1,000 +14.3%
Value US$4,470
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
4.46
Quantity 2,752 +64.8%
Value US$12,274
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
4.40
Quantity 3,248 +324.8%
Value US$14,291
2.1
Epstein David R Non-Executive Director
Transaction date
Purchase
Price
4.34
Quantity 1,000 +inf%
Value US$4,340
Flagship Ventures Fund IV General Partner LLC Large shareholder
Transaction date
Purchase
Price
16.00
Quantity 281,250 +1.6%
Value US$4,500,000
Flagship Ventures Fund V General Partner LLC Large shareholder
Transaction date
Purchase
Price
16.00
Quantity 281,250 +1.6%
Value US$4,500,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-11-08 2023-11-08 PlS Planned sale
McHale Duncan

Chief Medical Officer

Officer
2,721 +44.6%
349.68
US$3,193,289 		2,721 +44.6% 349.68 US$3,193,289
2023-11-08 2023-11-08 PlS Planned sale
Bodmer Mark

CSO, President of R&D

Officer
3,260 +48.2%
251.07
US$722,161 		3,260 +48.2% 251.07 US$722,161
2023-11-08 2023-11-08 PlS Planned sale
Thorell Marella

Chief Financial Officer

Officer
16,930 -33.7%
30.68
US$2,977,715 		16,930 -33.7% 30.68 US$2,977,715
2023-11-08 2023-11-08 PlS Planned sale
GILL SIMBA

President & CEO

Executive Director
172 -1.0%
0.33
US$57 		172 -1.0% 0.33 US$57
2023-11-03 2023-11-02 PlS Planned sale
Thorell Marella

Chief Financial Officer

Officer
3,999 -18.5%
0.33
US$1,320 		3,999 -18.5% 0.33 US$1,320
2023-11-03 2023-11-02 PlS Planned sale
Bodmer Mark

CSO, President of R&D

Officer
6,854 -23.5%
0.33
US$2,262 		6,854 -23.5% 0.33 US$2,262
2023-11-03 2023-11-02 PlS Planned sale
McHale Duncan

Chief Medical Officer

Officer
6,854 -33.5%
0.33
US$2,262 		6,854 -33.5% 0.33 US$2,262
2023-09-29 2023-09-28 PlS Planned sale
GILL SIMBA

President & CEO

Executive Director
1,996 -10.6%
3.94
US$7,864 		1,996 -10.6% 3.94 US$7,864
2023-08-09 2023-08-08 PlS Planned sale
Thorell Marella

Chief Financial Officer

Officer
2,004 -18.1%
9.51
US$19,058 		2,004 -18.1% 9.51 US$19,058
2023-08-09 2023-08-08 PlS Planned sale
GILL SIMBA

President & CEO

Executive Director
342 -8.3%
9.51
US$3,252 		342 -8.3% 9.51 US$3,252
2023-08-09 2023-08-08 PlS Planned sale
Bodmer Mark

CSO, President of R&D

Officer
3,128 -15.8%
9.51
US$29,747 		3,128 -15.8% 9.51 US$29,747
2023-08-09 2023-08-08 PlS Planned sale
McHale Duncan

Chief Medical Officer

Officer
3,434 -30.2%
9.51
US$32,657 		3,434 -30.2% 9.51 US$32,657
2023-07-13 2023-07-11 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
3,246,753 +474.0%
2.31
US$7,499,999 		3,246,753 +474.0% 2.31 US$7,499,999
2023-07-13 2023-07-11 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
1,082,251 +263.3%
2.31
US$2,500,000 		1,082,251 +263.3% 2.31 US$2,500,000
2023-07-13 2023-07-11 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
1,082,251 +285.1%
2.31
US$2,500,000 		1,082,251 +285.1% 2.31 US$2,500,000
2023-06-12 2023-05-23 PlS Planned sale
Bodmer Mark

CSO, President of R&D

Officer
22,571 -7.9%
0.14
US$3,201 		22,571 -7.9% 0.14 US$3,201
2023-05-10 2023-05-08 PlS Planned sale
Thorell Marella

Chief Financial Officer

Officer
38,531 -29.6%
0.13
US$4,836 		38,531 -29.6% 0.13 US$4,836
2023-05-10 2023-05-08 PlS Planned sale
Bodmer Mark

CSO, President of R&D

Officer
68,014 -19.3%
0.13
US$8,536 		68,014 -19.3% 0.13 US$8,536
2023-05-10 2023-05-08 PlS Planned sale
GILL SIMBA

President & CEO

Executive Director
3,537 -5.7%
0.13
US$444 		3,537 -5.7% 0.13 US$444
2023-05-10 2023-05-08 PlS Planned sale
McHale Duncan

Chief Medical Officer

Officer
66,730 -40.6%
0.13
US$8,375 		66,730 -40.6% 0.13 US$8,375
2023-01-23 2023-01-23 S Sale
CARRIERE STEPHEN J

Principal Accounting Officer

Officer
151 -42.7%
1.06
US$160 		151 -42.7% 1.06 US$160
2022-06-01 2022-05-27 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
13,698,630 +inf%
1.46
US$20,000,000 		13,698,630 +inf% 1.46 US$20,000,000
2022-06-01 2022-05-27 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
6,849,315 +499.8%
1.46
US$10,000,000 		6,849,315 +499.8% 1.46 US$10,000,000
2022-06-01 2022-05-27 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
1,369,863 +33.2%
1.46
US$2,000,000 		1,369,863 +33.2% 1.46 US$2,000,000
2022-06-01 2022-05-27 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
1,095,890 +138.5%
1.46
US$1,599,999 		1,095,890 +138.5% 1.46 US$1,599,999
2022-06-01 2022-05-27 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
4,383,561 +136.7%
1.46
US$6,399,999 		4,383,561 +136.7% 1.46 US$6,399,999
2022-05-31 2022-05-27 B Purchase
Darzi Lord Ara
Non-Executive Director
342,465 +inf%
1.46
US$499,999 		342,465 +inf% 1.46 US$499,999
2022-05-31 2022-05-27 B Purchase
McHale Duncan

Chief Medical Officer

Officer
34,246 +inf%
1.46
US$49,999 		34,246 +inf% 1.46 US$49,999
2022-05-31 2022-05-27 B Purchase
2.1
Epstein David R
Non-Executive Director
17,123 +25.6%
1.46
US$25,000 		17,123 +25.6% 1.46 US$25,000
2021-02-04 2021-02-02 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
46,429 +1.1%
15.00
US$696,435 		46,429 +1.1% 15.00 US$696,435
2021-02-04 2021-02-02 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
37,143 +2.8%
15.00
US$557,145 		37,143 +2.8% 15.00 US$557,145
2021-02-04 2021-02-02 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
9,285 +1.2%
15.00
US$139,275 		9,285 +1.2% 15.00 US$139,275
2021-02-04 2021-02-02 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
37,143 +1.2%
15.00
US$557,145 		37,143 +1.2% 15.00 US$557,145
2020-12-14 2020-12-11 B Purchase
2.1
Epstein David R
Non-Executive Director
200 +1.1%
7.02
US$1,404 		200 +1.1% 7.02 US$1,404
2020-12-14 2020-12-11 B Purchase
2.1
Epstein David R
Non-Executive Director
500 +2.9%
6.98
US$3,490 		500 +2.9% 6.98 US$3,490
2020-12-14 2020-12-11 B Purchase
2.1
Epstein David R
Non-Executive Director
1,000 +6.2%
6.91
US$6,910 		1,000 +6.2% 6.91 US$6,910
2020-12-14 2020-12-11 B Purchase
2.1
Epstein David R
Non-Executive Director
800 +5.3%
7.16
US$5,728 		800 +5.3% 7.16 US$5,728
2020-12-14 2020-12-11 B Purchase
2.1
Epstein David R
Non-Executive Director
4,970 +48.6%
6.49
US$32,255 		4,970 +48.6% 6.49 US$32,255
2020-12-14 2020-12-11 B Purchase
2.1
Epstein David R
Non-Executive Director
30 +0.3%
6.45
US$194 		30 +0.3% 6.45 US$194
2020-12-14 2020-12-11 B Purchase
2.1
Epstein David R
Non-Executive Director
200 +2.0%
6.40
US$1,280 		200 +2.0% 6.40 US$1,280
2020-12-02 2020-12-01 S Sale
Liu Xiaoli Jacqueline

Principal Accounting Officer

Officer
3,000 -100.0%
5.17
US$15,510 		3,000 -100.0% 5.17 US$15,510
2020-09-01 2020-08-31 B Purchase
2.1
Epstein David R
Non-Executive Director
1,000 +11.1%
4.58
US$4,580 		1,000 +11.1% 4.58 US$4,580
2020-09-01 2020-08-31 B Purchase
2.1
Epstein David R
Non-Executive Director
1,000 +12.5%
4.48
US$4,480 		1,000 +12.5% 4.48 US$4,480
2020-09-01 2020-08-31 B Purchase
2.1
Epstein David R
Non-Executive Director
1,000 +14.3%
4.47
US$4,470 		1,000 +14.3% 4.47 US$4,470
2020-09-01 2020-08-31 B Purchase
2.1
Epstein David R
Non-Executive Director
2,752 +64.8%
4.46
US$12,274 		2,752 +64.8% 4.46 US$12,274
2020-09-01 2020-08-28 B Purchase
2.1
Epstein David R
Non-Executive Director
3,248 +324.8%
4.40
US$14,291 		3,248 +324.8% 4.40 US$14,291
2020-09-01 2020-08-28 B Purchase
2.1
Epstein David R
Non-Executive Director
1,000 +inf%
4.34
US$4,340 		1,000 +inf% 4.34 US$4,340
2020-07-01 2020-06-29 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
1,666,667 +69.1%
3.75
US$6,250,001 		1,666,667 +69.1% 3.75 US$6,250,001
2020-07-01 2020-06-29 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
1,333,333 +inf%
3.75
US$4,999,999 		1,333,333 +inf% 3.75 US$4,999,999
2020-07-01 2020-06-29 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
333,333 +74.3%
3.75
US$1,249,999 		333,333 +74.3% 3.75 US$1,249,999
2020-07-01 2020-06-29 B Purchase
3.0
Flagship Ventures Fund IV General Partner LLC
Large shareholder
1,333,333 +72.6%
3.75
US$4,999,999 		1,333,333 +72.6% 3.75 US$4,999,999
2018-05-15 2018-05-11 B Purchase Flagship Ventures Fund IV General Partner LLC Large shareholder
281,250 +1.6%
16.00
US$4,500,000 		281,250 +1.6% 16.00 US$4,500,000
2018-05-15 2018-05-11 B Purchase Flagship Ventures Fund V General Partner LLC Large shareholder
281,250 +1.6%
16.00
US$4,500,000 		281,250 +1.6% 16.00 US$4,500,000
Explore more

More insider trading research around Evelo Biosciences Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America